NOVOS

NOVOS occupies a defensible middle ground in consumer longevity: more scientifically credible than mass-market supplement brands, more accessible than clinical interventions, and structured to build a measurable feedback loop rather than sell a one-off bottle. Founded in 2020 by CEO Chris Mirabile with physician co-founder Kris Verburgh and organized as a public benefit corporation, NOVOS anchors its stack to the hallmarks of aging: NOVOS Core is a 12-ingredient formulation targeting multiple aging pathways at once, NOVOS Boost adds NMN/NAD+ support, and NOVOS Age is an at-home dried-blood-spot epigenetic test reporting biological age, pace of aging via the well-validated DunedinPACE biomarker, organ age, and telomere length. That test-plus-supplement architecture is the strategic core — it turns customers into repeat measurers tracking their own aging over time, driving retention and generating data most competitors lack. The credibility signal is unusually strong for a consumer brand: an advisor bench including George Church, Matt Kaeberlein, and Joao Pedro de Magalhaes, and company-cited research including a six-month case study reporting favorable DunedinPACE shifts. Pairing a genuinely validated third-party aging clock (DunedinPACE, ICC > 0.96, backed by 45+ studies) with a science-forward multi-ingredient product lets NOVOS market on evidence rather than hype, positioning it to capture the growing cohort of consumers who want quantified, hallmarks-based longevity rather than a random NMN pill.